Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368840 | 0.86 | MEN1 (0.46) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL14026851 | 0.80 | MEN1 (0.46) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL14027740 | 0.80 | MAOA (0.50) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL15764454 | 0.78 | TDP1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12954627 | 0.78 | MAOA (0.44) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL30387270 | 0.77 | MEN1 (0.51) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12413739 | 0.77 | MEN1 (0.44) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL3122792 | 0.75 | MEN1 (0.53) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL23921399 | 0.75 | MEN1 (0.51) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL19751300 | 0.75 | MEN1 (0.41) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116809-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | ASCENDIS PHARMA OPHTHALMOLOGY DIVISION A/S (DK) | 2023-04-13 | — | — | US | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | ASCENDIS PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S (DK) | 2018-02-15 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116809-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | MEN1 3163/4885GAA 409/4885KMT2A 4600/4885 |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | MEN1 3163/4885GAA 409/4885KMT2A 4600/4885 |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | TNF, ADAMTS5, ADAMTS1 | MEN1 1495/4885GAA 653/4885KMT2A 3627/4885 |
| US-10653795-B2 | — | PTMS, MSN, CD44 | MEN1 3272/4885GAA 115/4885KMT2A 3217/4885 |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | IL1A, IL1B, IL1R1 | MEN1 3479/4885GAA 1909/4885KMT2A 2549/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | MEN1 3497/4885GAA 346/4885KMT2A 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.